Brilinta is not an anticoagulant. It is an antiplatelet medication. Both drug types help prevent dangerous blood clots, but they work through completely different mechanisms, and the distinction matters for your treatment.
How Brilinta Works
Brilinta (ticagrelor) prevents blood clots by stopping platelets from clumping together. Platelets are small cell fragments in your blood that rush to the site of an injury and stick to each other to form a clot. Brilinta blocks a specific receptor on the surface of platelets, locking it in an inactive state so that platelets can’t receive the chemical signal that tells them to aggregate.
What makes Brilinta different from older antiplatelet drugs like clopidogrel is that its binding is reversible. Older drugs in the same class permanently disable each platelet they touch, meaning the effect only wears off as your body produces new platelets. Brilinta releases its grip on the receptor when the drug clears your system, which gives it a faster on-and-off action.
Antiplatelet vs. Anticoagulant
The confusion between these two categories is common because both reduce clotting. The difference comes down to which part of the clotting process each drug targets. Antiplatelet agents like Brilinta prevent platelets from activating and sticking together. Anticoagulants like warfarin or rivarelbán target the coagulation cascade, a chain reaction of proteins in your blood that produces fibrin, the mesh-like substance that reinforces a clot.
Think of it this way: platelets form the initial plug at a wound site, and the coagulation cascade weaves a net around that plug to strengthen it. Antiplatelets stop the plug from forming. Anticoagulants stop the net. Brilinta works on the plug side of this equation.
What Brilinta Is Prescribed For
Brilinta is used in several situations involving arterial clots. After an acute coronary syndrome event (a heart attack or severe chest pain caused by reduced blood flow to the heart), it’s typically started with a one-time loading dose and then taken twice daily. For the first year after the event, the maintenance dose is 90 mg twice daily. After that first year, the dose drops to 60 mg twice daily for longer-term protection.
It’s also prescribed for people with stable coronary artery disease who haven’t had a heart attack or stroke, at 60 mg twice daily. For acute ischemic stroke or a transient ischemic attack (a “mini-stroke”), a loading dose is followed by 90 mg twice daily for up to 30 days.
In most of these scenarios, Brilinta is taken alongside low-dose aspirin, another antiplatelet drug. This combination is called dual antiplatelet therapy (DAPT). Current guidelines recommend DAPT for up to one year after a coronary event, with the option to transition to Brilinta alone after at least one month if bleeding risk is a concern.
Bleeding Risk
Because Brilinta impairs your blood’s ability to form clots, bleeding is the most significant risk. In clinical trials comparing Brilinta 60 mg plus aspirin against aspirin alone over three years, 29% of patients on the combination experienced a bleeding event, compared to 12% on aspirin alone. Fatal or life-threatening bleeding occurred in 2.4% of the Brilinta group versus 1.1% on placebo. Put another way, for every 81 patients treated with Brilinta plus aspirin for three years, one patient experienced an additional major bleed that wouldn’t have happened on aspirin alone.
Brilinta is contraindicated if you have a history of intracranial hemorrhage (bleeding in the brain) or any active pathological bleeding, such as a bleeding peptic ulcer. The risk of recurrent brain bleeding is too high in these populations.
Shortness of Breath: A Common Side Effect
One side effect that catches many patients off guard is dyspnea, or shortness of breath. In the large PLATO trial, 13.8% of patients on Brilinta reported it, compared to 7.8% on clopidogrel. A real-world observational study found even higher numbers: 56% of Brilinta patients reported some degree of breathlessness at three weeks, though this dropped to about 33% by twelve months. The sensation is typically mild and tends to improve over time, but it’s distinct enough that patients sometimes worry something is wrong with their heart or lungs.
This side effect is related to how ticagrelor interacts with a chemical signaling pathway beyond its platelet-blocking role. It is not a sign that the drug is harming your cardiovascular system, but it’s worth mentioning to your care team if it’s persistent or bothersome, since alternative antiplatelet options exist.